IL267519B2 - Factor XI/XIA for use in the prevention, treatment, management, or reduction of the risk of stroke or thromboembolism in a patient with end-stage renal disease - Google Patents

Factor XI/XIA for use in the prevention, treatment, management, or reduction of the risk of stroke or thromboembolism in a patient with end-stage renal disease

Info

Publication number
IL267519B2
IL267519B2 IL267519A IL26751919A IL267519B2 IL 267519 B2 IL267519 B2 IL 267519B2 IL 267519 A IL267519 A IL 267519A IL 26751919 A IL26751919 A IL 26751919A IL 267519 B2 IL267519 B2 IL 267519B2
Authority
IL
Israel
Prior art keywords
antibody
fxi
fxia
seq
amino acid
Prior art date
Application number
IL267519A
Other languages
English (en)
Hebrew (he)
Other versions
IL267519B1 (en
IL267519A (en
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of IL267519A publication Critical patent/IL267519A/en
Publication of IL267519B1 publication Critical patent/IL267519B1/en
Publication of IL267519B2 publication Critical patent/IL267519B2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/36—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Hematology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
IL267519A 2016-12-23 2017-12-22 Factor XI/XIA for use in the prevention, treatment, management, or reduction of the risk of stroke or thromboembolism in a patient with end-stage renal disease IL267519B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662438654P 2016-12-23 2016-12-23
US201762589851P 2017-11-22 2017-11-22
PCT/IB2017/058345 WO2018116267A2 (en) 2016-12-23 2017-12-22 Methods of treatment with anti-factor xi/xia antibodies

Publications (3)

Publication Number Publication Date
IL267519A IL267519A (en) 2019-08-29
IL267519B1 IL267519B1 (en) 2024-12-01
IL267519B2 true IL267519B2 (en) 2025-04-01

Family

ID=61022382

Family Applications (2)

Application Number Title Priority Date Filing Date
IL267519A IL267519B2 (en) 2016-12-23 2017-12-22 Factor XI/XIA for use in the prevention, treatment, management, or reduction of the risk of stroke or thromboembolism in a patient with end-stage renal disease
IL316673A IL316673A (en) 2016-12-23 2017-12-22 Factor XI/XIA FOR USE IN PREVENTING, TREATING, MANAGING OR REDUCING THE RISK OF STROKE OR THROMBOEMBOLISM IN A SUBJECT AFFLICTED WITH END STAGE RENAL DISEASE

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL316673A IL316673A (en) 2016-12-23 2017-12-22 Factor XI/XIA FOR USE IN PREVENTING, TREATING, MANAGING OR REDUCING THE RISK OF STROKE OR THROMBOEMBOLISM IN A SUBJECT AFFLICTED WITH END STAGE RENAL DISEASE

Country Status (9)

Country Link
US (3) US20200231701A1 (https=)
EP (1) EP3558370A2 (https=)
JP (3) JP7110199B2 (https=)
KR (3) KR102702288B1 (https=)
CN (2) CN110325211A (https=)
AU (2) AU2017383537B2 (https=)
CA (1) CA3048157A1 (https=)
IL (2) IL267519B2 (https=)
WO (1) WO2018116267A2 (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6799530B2 (ja) 2014-10-01 2020-12-16 メディミューン リミテッド チカグレロルに対する抗体および使用方法
UY36751A (es) 2015-06-26 2017-01-31 Novartis Ag Anticuerpos de factor xi y métodos de uso
TW201802121A (zh) 2016-05-25 2018-01-16 諾華公司 抗因子XI/XIa抗體之逆轉結合劑及其用途
IL267519B2 (en) * 2016-12-23 2025-04-01 Novartis Ag Factor XI/XIA for use in the prevention, treatment, management, or reduction of the risk of stroke or thromboembolism in a patient with end-stage renal disease
AU2017383232B2 (en) 2016-12-23 2024-09-12 Novartis Ag Factor XI antibodies and methods of use
KR102880762B1 (ko) 2018-09-20 2025-11-03 에스에프제이 파마 엑스, 인코포레이티드 티카그렐러 활성을 반전시키는 방법
KR20210151774A (ko) 2019-04-16 2021-12-14 쓰촨 케룬-바이오테크 바이오파마수티컬 컴퍼니 리미티드 항-FXI/FXIa 항체 및 그 용도
CN110423278B (zh) * 2019-08-08 2020-07-17 上海博槿生物科技有限公司 一种抗凝血因子XI活化形式因子XIa的抗体及其制备方法和应用
US20230071973A1 (en) * 2019-12-20 2023-03-09 Anthos Therapeutics, Inc. Pharmaceutical formulations and dosage regimens for factor xi/xia antibodies
EP4177274A4 (en) * 2020-07-02 2024-04-03 Beijing Tuo Jie Biopharmaceutical Co. Ltd. Anti-fxi/fxia antibody, antigen-binding fragment thereof, and pharmaceutical use thereof
TW202405022A (zh) * 2022-06-24 2024-02-01 美商安瑟斯治療公司 與抗因子ｘｉ／因子ｘｉａ抗體之組合療法
WO2025201156A1 (zh) * 2024-03-28 2025-10-02 施能康生物医药（苏州）有限公司 靶向凝血因子xi的核酸及其用途

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013167669A1 (en) * 2012-05-10 2013-11-14 Bayer Pharma Aktiengesellschaft Antibodies capable of binding to the coagulation factor xi and/or its activated form factor xia and uses thereof

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4458066A (en) 1980-02-29 1984-07-03 University Patents, Inc. Process for preparing polynucleotides
DE3572982D1 (en) 1984-03-06 1989-10-19 Takeda Chemical Industries Ltd Chemically modified lymphokine and production thereof
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
JP3101690B2 (ja) 1987-03-18 2000-10-23 エス・ビィ・２・インコーポレイテッド 変性抗体の、または変性抗体に関する改良
US5336603A (en) 1987-10-02 1994-08-09 Genentech, Inc. CD4 adheson variants
KR900005995A (ko) 1988-10-31 1990-05-07 우메모또 요시마사 변형 인터류킨-2 및 그의 제조방법
WO1990006952A1 (fr) 1988-12-22 1990-06-28 Kirin-Amgen, Inc. Facteur de stimulation de colonies de granulocytes modifies chimiquement
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5112946A (en) 1989-07-06 1992-05-12 Repligen Corporation Modified pf4 compositions and methods of use
FR2650598B1 (fr) 1989-08-03 1994-06-03 Rhone Poulenc Sante Derives de l'albumine a fonction therapeutique
WO1991006570A1 (en) 1989-10-25 1991-05-16 The University Of Melbourne HYBRID Fc RECEPTOR MOLECULES
US5349053A (en) 1990-06-01 1994-09-20 Protein Design Labs, Inc. Chimeric ligand/immunoglobulin molecules and their uses
WO1992010591A1 (en) 1990-12-14 1992-06-25 Cell Genesys, Inc. Chimeric chains for receptor-associated signal transduction pathways
EP0571613B1 (en) 1991-12-13 2003-09-17 Xoma Corporation Methods and materials for preparation of modified antibody variable domains and therapeutic uses thereof
US5622929A (en) 1992-01-23 1997-04-22 Bristol-Myers Squibb Company Thioether conjugates
FR2686899B1 (fr) 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
FR2686901A1 (fr) 1992-01-31 1993-08-06 Rhone Poulenc Rorer Sa Nouveaux polypeptides antithrombotiques, leur preparation et compositions pharmaceutiques les contenant.
US5447851B1 (en) 1992-04-02 1999-07-06 Univ Texas System Board Of Dna encoding a chimeric polypeptide comprising the extracellular domain of tnf receptor fused to igg vectors and host cells
US5837458A (en) 1994-02-17 1998-11-17 Maxygen, Inc. Methods and compositions for cellular and metabolic engineering
US5834252A (en) 1995-04-18 1998-11-10 Glaxo Group Limited End-complementary polymerase reaction
US5605793A (en) 1994-02-17 1997-02-25 Affymax Technologies N.V. Methods for in vitro recombination
HUT76369A (en) 1994-07-29 1997-08-28 Smithkline Beecham Corp Novel soluble protein compounds
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
US20070190059A1 (en) * 1996-01-17 2007-08-16 Smithkline Beecham Corporation Antithrombotic agents
US20030235587A1 (en) * 1998-08-07 2003-12-25 Feuerstein Giora Z. Anticoagulant agents useful in treatment of thrombosis
MA24512A1 (fr) * 1996-01-17 1998-12-31 Univ Vermont And State Agrienl Procede pour la preparation d'agents anticoagulants utiles dans le traitement de la thrombose
JP4046354B2 (ja) 1996-03-18 2008-02-13 ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム 増大した半減期を有する免疫グロブリン様ドメイン
WO1998023289A1 (en) 1996-11-27 1998-06-04 The General Hospital Corporation MODULATION OF IgG BINDING TO FcRn
US6277375B1 (en) 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
EP1958962A3 (en) 1997-06-12 2013-05-01 Novartis International Pharmaceutical Ltd. Artificial antibody polypeptides
WO2000007626A1 (en) * 1998-08-07 2000-02-17 Smithkline Beecham Corporation Use of anti-coagulation factor antibodies as long-lasting protective agents
US6624295B1 (en) * 1998-08-28 2003-09-23 Genentech, Inc. Human anti-factor IX/IXa antibodies
EP2213743A1 (en) 2000-04-12 2010-08-04 Human Genome Sciences, Inc. Albumin fusion proteins
KR20070116192A (ko) * 2000-05-15 2007-12-06 스미스클라인 비참 코포레이션 항혈전제
JP2011504371A (ja) * 2007-11-21 2011-02-10 オレゴン ヘルス アンド サイエンス ユニバーシティー 抗第ｘｉ因子モノクローナル抗体およびその使用方法
TR201820051T4 (tr) * 2008-06-19 2019-01-21 Prothix Bv Anti-faktör XI Antikorlarının Trombüs Oluşumunun Engellenmesi Veya Tedavisi İçin Kullanılması
PT2373691T (pt) * 2008-12-18 2019-05-08 Univ Vanderbilt Anticorpos anti-fxi e métodos de utilização
IL212911A0 (en) * 2011-05-16 2011-07-31 Omrix Biopharmaceuticals Ltd Immunoglobulin reduced in thrombogenic contaminants and preparation thereof
UY36751A (es) * 2015-06-26 2017-01-31 Novartis Ag Anticuerpos de factor xi y métodos de uso
IL267519B2 (en) * 2016-12-23 2025-04-01 Novartis Ag Factor XI/XIA for use in the prevention, treatment, management, or reduction of the risk of stroke or thromboembolism in a patient with end-stage renal disease

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013167669A1 (en) * 2012-05-10 2013-11-14 Bayer Pharma Aktiengesellschaft Antibodies capable of binding to the coagulation factor xi and/or its activated form factor xia and uses thereof

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
BAGUL, A., ET AL., TUNNELLED CATHETERS FOR THE HAEMODIALYSIS PATIENT., 1 January 2007 (2007-01-01) *
DINKAR KAW, DEEPAK MALHOTRA, HEMATOLOGY: ISSUES IN THE DIALYSIS PATIENT: PLATELET DYSFUNCTION AND END-STAGE RENAL DISEASE, 18 July 2006 (2006-07-18) *
SCHROR, K., ASPIRIN AND PLATELETS: THE ANTIPLATELET ACTION OF ASPIRIN AND ITS ROLE IN THROMBOSIS TREATMENT AND PROPHYLAXIS, 1 January 1997 (1997-01-01) *

Also Published As

Publication number Publication date
US20200231701A1 (en) 2020-07-23
JP2020504110A (ja) 2020-02-06
EP3558370A2 (en) 2019-10-30
AU2017383537B2 (en) 2024-10-03
IL316673A (en) 2024-12-01
IL267519B1 (en) 2024-12-01
JP2024116221A (ja) 2024-08-27
US20250197522A1 (en) 2025-06-19
JP7500662B2 (ja) 2024-06-17
CN118320078A (zh) 2024-07-12
KR102702288B1 (ko) 2024-09-05
US20230002507A1 (en) 2023-01-05
WO2018116267A2 (en) 2018-06-28
WO2018116267A3 (en) 2018-08-02
AU2024287181A1 (en) 2025-03-06
JP2022141831A (ja) 2022-09-29
JP7110199B2 (ja) 2022-08-01
KR20260023597A (ko) 2026-02-20
CN110325211A (zh) 2019-10-11
IL267519A (en) 2019-08-29
KR20190099256A (ko) 2019-08-26
KR102918597B1 (ko) 2026-01-28
KR20240134248A (ko) 2024-09-06
CA3048157A1 (en) 2018-06-28
AU2017383537A1 (en) 2019-06-27

Similar Documents

Publication Publication Date Title
US20250197522A1 (en) Methods of treatment with anti-factor xi/xia antibodies
US20240067750A1 (en) Factor xi antibodies and methods of use
US20250101130A1 (en) Factor xi antibodies and methods of use
CA3048156C (en) Factor xi antibodies and methods of use